News for Healthier Living
Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Substudy Supports Reduced Risk of Metastasis and Death
An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide -- a next-generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) -- plus hormone therapy before and after prostate cancer surgery, was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care.
The substudy, co-led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, was presented at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain and published today in European Urology.
October 26, 2026
November 1 2026October 30 2026October 29 2026October 28 2026October 27 2026October 26 2026October 25 2026October 24 2026October 23 2026October 22 2026October 21 2026October 20 2026October 19 2026
|
|
|
|
|